Altimmune/$ALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Altimmune
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Ticker
$ALT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
59
ISIN
US02155H2004
Website
Altimmune Metrics
BasicAdvanced
$359M
-
-$1.25
1.11
-
Price and volume
Market cap
$359M
Beta
1.11
52-week high
$9.46
52-week low
$2.90
Average daily volume
8.5M
Financial strength
Current ratio
15.846
Quick ratio
15.543
Long term debt to equity
0.944
Total debt to equity
1.116
Interest coverage (TTM)
-10,910.33%
Profitability
EBITDA (TTM)
-98.033
Gross margin (TTM)
-382,730.00%
Net profit margin (TTM)
-451,200.00%
Operating margin (TTM)
-490,965.00%
Effective tax rate (TTM)
0.75%
Management effectiveness
Return on assets (TTM)
-35.51%
Return on equity (TTM)
-57.28%
Valuation
Price to revenue (TTM)
15,992.78
Price to book
2.43
Price to tangible book (TTM)
2.43
Price to free cash flow (TTM)
-3.981
Free cash flow yield (TTM)
-25.12%
Free cash flow per share (TTM)
-111.28%
Growth
Revenue change (TTM)
-95.12%
Earnings per share change (TTM)
-21.28%
3-year revenue growth (CAGR)
-82.30%
3-year earnings per share growth (CAGR)
-19.42%
What the Analysts think about Altimmune
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Bulls say / Bears say
Altimmune's lead candidate, pemvidutide, demonstrated significant weight loss in a Phase 2 obesity trial, with the highest dose achieving a 15.6% reduction over 48 weeks, indicating strong efficacy in the competitive weight loss market. (investorplace.com)
The company successfully closed a $132 million public offering, enhancing its financial position to advance clinical trials and scale manufacturing for its pipeline products. (stocktitan.net)
Altimmune's inclusion in the Nasdaq Biotechnology Index elevates its profile, potentially attracting more institutional investors and increasing stock liquidity. (fool.com)
Altimmune reported a net loss of $23.18 million in Q4 2024, reflecting ongoing financial challenges common in clinical-stage biopharmaceutical companies. (google.com)
Schroder Investment Management Group reduced its stake by selling 45,544 shares, which may signal waning confidence among institutional investors. (americanbankingnews.com)
Despite positive trial results, Altimmune's stock price has experienced volatility, with a 52-week range between $3.55 and $11.16, indicating market uncertainty about its long-term prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Altimmune Financial Performance
Revenues and expenses
Altimmune Earnings Performance
Company profitability
Altimmune News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
GlobeNewsWire·5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
GlobeNewsWire·1 week ago
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Altimmune stock?
Altimmune (ALT) has a market cap of $359M as of July 08, 2025.
What is the P/E ratio for Altimmune stock?
The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of July 08, 2025.
Does Altimmune stock pay dividends?
No, Altimmune (ALT) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Altimmune dividend payment date?
Altimmune (ALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Altimmune?
Altimmune (ALT) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.